Jazz Pharmaceuticals, Inc. (JAZZ) Dividend History

Company News

• Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

  Zymeworks, a clinical-stage biotechnology company, will report its Q2 2025 financial results on August 7, 2025, and participate in upcoming investor conferences. The company has received regulatory approvals for zanidatamab, a HER2-targeted bispecific antibody for biliary tract cancer treatment.

  GlobeNewswire Inc.

  Featured Companies: ZYME
• Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker

  Billionaire Seth Klarman's Baupost Group significantly reduced its stake in Alphabet (Google's parent company) while increasing its position in Jazz Pharmaceuticals, a historically cheap and under-the-radar drugmaker.

  The Motley Fool

  Featured Companies: GOOG GOOGL
• Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices

  Jazz Pharmaceuticals and Hikma Pharmaceuticals are accused of conspiring to delay the release of a generic version of Jazz's narcolepsy drug Xyrem, resulting in higher prices for health plans. The plaintiffs allege that Jazz made payments to delay the entry of a rival generic and monopolized distribution using a specialty pharmacy.

  Benzinga
• UBS cuts Jazz Pharmaceuticals target to $113 from $117 By Investing.com - Investing.com

  UBS revised its price target for Jazz Pharmaceuticals to $113 from $117, citing challenges within the company's Sleep franchise and the failure of its Essential Tremor treatment in a clinical trial.

  Investing.com
• Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates

  Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.

  Zacks Investment Research

  Featured Companies: ALNY ANIP SRPT